Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia 

 Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia 

Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia 

Shots:

  • The approval is based on non-inferiority data demonstrating biosimilarity between Retacrit and the reference product, Epogen & Procrit
  • In May, 2016 Pfizer and Vifor Pharma collaborated for the commercialization of retacrit in certain therapeutic areas
  • Retacrit (epoetin alfa) a biosimilar to Epogen & Procrit, is an erythropoiesis-stimulating agent (ESA) indicated for anemia and reduction in allogeneic red blood cell (RBC) transfusionT

Click here to read full press release/ article | Ref: Pfizer | Image: Market Exclusive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post